keyword
MENU ▼
Read by QxMD icon Read
search

Metastatic breast cancer

keyword
https://www.readbyqxmd.com/read/29342159/prediction-of-novel-target-genes-and-pathways-involved-in-bevacizumab-resistant-colorectal-cancer
#1
Precious Takondwa Makondi, Chia-Hwa Lee, Chien-Yu Huang, Chi-Ming Chu, Yu-Jia Chang, Po-Li Wei
Bevacizumab combined with cytotoxic chemotherapy is the backbone of metastatic colorectal cancer (mCRC) therapy; however, its treatment efficacy is hampered by therapeutic resistance. Therefore, understanding the mechanisms underlying bevacizumab resistance is crucial to increasing the therapeutic efficacy of bevacizumab. The Gene Expression Omnibus (GEO) database (dataset, GSE86525) was used to identify the key genes and pathways involved in bevacizumab-resistant mCRC. The GEO2R web tool was used to identify differentially expressed genes (DEGs)...
2018: PloS One
https://www.readbyqxmd.com/read/29341112/conditionally-reprogrammed-cells-crc-methodology-does-not-allow-the-in-vitro-expansion-of-patient-derived-primary-and-metastatic-lung-cancer-cells
#2
Giovanni Sette, Valentina Salvati, Ilenia Giordani, Emanuela Pillozzi, Denise Quacquarini, Enrico Duranti, Francesca De Nicola, Matteo Pallocca, Maurizio Fanciulli, Mario Falchi, Roberto Pallini, Ruggero De Maria, Adriana Eramo
Availability of tumor and non-tumor patient-derived models would promote the development of more effective therapeutics for Non Small Cell Lung Cancer (NSCLC). Recently, conditionally reprogrammed cells (CRC) methodology demonstrated exceptional potential for the expansion of epithelial cells from patient tissues. However, the possibility to expand patient-derived lung cancer cells using CRC protocols is controversial. Here, we used CRC approach to expand cells from non-tumoral and tumor biopsies of patients with primary or metastatic NSCLC as well as pulmonary metastases of colorectal or breast cancers...
January 17, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29340907/harnessing-a-different-dependency-how-to-identify-and-target-androgen-receptor-positive-versus-quadruple-negative-breast-cancer
#3
REVIEW
Jessica L Christenson, Jane B Trepel, Haythem Y Ali, Sunmin Lee, Joel R Eisner, Edwina S Baskin-Bey, Anthony D Elias, Jennifer K Richer
The androgen receptor (AR) is a promising therapeutic target for a subset of triple-negative breast cancers (TNBCs) in which AR is expressed. However, the mechanistic action of AR and the degree to which primary and metastatic tumors depend on AR, both before and after conventional treatment, remain to be defined. We discuss preclinical and clinical data for AR+ TNBC, the difficulties in monitoring AR protein levels, new methods for determining AR status, the influence of AR on "stemness" in the context of TNBC, the role of combined inhibition of sex steroid production and AR, and the role of AR in regulation of the immune system...
January 16, 2018: Hormones & Cancer
https://www.readbyqxmd.com/read/29340882/circulating-small-sized-endothelial-microparticles-as-predictors-of-clinical-outcome-after-chemotherapy-for-breast-cancer-an-exploratory-analysis
#4
Elisa García Garre, Ginés Luengo Gil, Silvia Montoro García, Enrique Gonzalez Billalabeitia, Marta Zafra Poves, Elena García Martinez, Vanessa Roldán Schilling, Esther Navarro Manzano, Alejandra Ivars Rubio, Gregory Y H Lip, Francisco Ayala de la Peña
PURPOSE: Therapeutic exploitation of angiogenesis in breast cancer has been limited by the lack of reliable biomarkers. Circulating small-sized endothelial microparticles (sEMP) are likely to play a significant role as messengers of angiogenesis. Higher levels of EMP have been observed in cancer patients, but their prognostic value in breast cancer is unknown. Our aim was to determine the value of circulating sEMP as a marker of response to chemotherapy in breast cancer. METHODS: We included patients with breast cancer treated with neoadjuvant or first-line chemotherapy...
January 16, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29340881/circulating-free-dna-integrity-and-concentration-as-independent-prognostic-markers-in-metastatic-breast-cancer
#5
Jie Cheng, Tim Holland-Letz, Markus Wallwiener, Harald Surowy, Katarina Cuk, Sarah Schott, Andreas Trumpp, Klaus Pantel, Christof Sohn, Andreas Schneeweiss, Barbara Burwinkel
PURPOSE: Non-invasive blood-based molecular markers have been investigated for cancer diagnosis and prognosis. Circulating free or cell-free DNA (cfDNA) variables have been shown to be putative markers in breast cancer prognosis. METHODS: Here, we investigated the potential prognostic ability of cfDNA concentration and cfDNA integrity (cfDI) in a study cohort of 268 patients by quantitative PCR. We compared cfDNA concentration and cfDI at baseline and after one cycle of therapy in metastatic breast cancer (MBC) patients...
January 16, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29340880/gata-3-is-superior-to-gcdfp-15-and-mammaglobin-to-identify-primary-and-metastatic-breast-cancer
#6
Yun-Bi Ni, Julia Y S Tsang, Mu-Min Shao, Siu-Ki Chan, Sai-Yin Cheung, Joanna Tong, Ka-Fai To, Gary M Tse
PURPOSE: Despite numerous studies on the utility of GATA-3 as breast cancer marker, its comparison with other breast markers, its concordance between primary and metastatic tumors and its expression in primary cancers from sites with frequent breast metastases remains unclear. METHODS: To address these questions, totally 993 invasive breast cancers (IBC), 254 paired nodal metastases, 23 distant metastases, and 208 lung carcinomas were included. GATA-3 expression was analyzed by immunohistochemistry and compared to other breast markers [gross cystic disease fluid protein 15 (GCDFP-15) and mammaglobin (MGB)]...
January 16, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29340103/anti-neoplastic-drugs-increase-caveolin-1-dependent-migration-invasion-and-metastasis-of-cancer-cells
#7
Natalia I Díaz-Valdivia, Claudia C Calderón, Jorge E Díaz, Lorena Lobos-González, Hugo Sepulveda, Rina J Ortíz, Samuel Martinez, Veronica Silva, Horacio J Maldonado, Patricio Silva, Sergio Wehinger, Verónica A Burzio, Vicente A Torres, Martín Montecino, Lisette Leyton, Andrew F G Quest
Expression of the scaffolding protein Caveolin-1 (CAV1) enhances migration and invasion of metastatic cancer cells. Yet, CAV1 also functions as a tumor suppressor in early stages of cancer, where expression is suppressed by epigenetic mechanisms. Thus, we sought to identify stimuli/mechanisms that revert epigenetic CAV1 silencing in cancer cells and evaluate how this affects their metastatic potential. We reasoned that restricted tissue availability of anti-neoplastic drugs during chemotherapy might expose cancer cells to sub-therapeutic concentrations, which activate signaling pathways and the expression of CAV1 to favor the acquisition of more aggressive traits...
December 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29339789/exosome-mediated-breast-cancer-chemoresistance-via-mir-155-transfer
#8
Juliana Carvalho Santos, Natália da Silva Lima, Luis Otavio Sarian, Ander Matheu, Marcelo Lima Ribeiro, Sophie Françoise Mauricette Derchain
Breast cancer remains the most prevalent cause of cancer mortality in woman worldwide due to the metastatic process and therapy resistance. Resistance against cancer therapy is partially attributed to cancer stem cells (CSCs). These cells arise from epithelial cells undergoing epithelial-to-mesenchymal transition (EMT) and might be responsible for tumor recurrence. In this study, we reported the relevance of miR-155 upregulation in chemoresistant cells associated with EMT. Notably, we found miR-155 induction in exosomes isolated from CSCs and resistant cells, followed by resistant cells' exosome transfer to the recipient sensitive cells...
January 16, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29339542/ampk-akt-double-negative-feedback-loop-in-breast-cancer-cells-regulates-their-adaptation-to-matrix-deprivation
#9
Manipa Saha, Saurav Kumar, Shoiab Bukhari, Sai A Balaji, Prashant Kumar, Sravanth K Hindupur, Annapoorni Rangarajan
Cell detachment from the extracellular matrix triggers anoikis. Disseminated tumor cells must adapt to survive matrix deprivation, while still retaining the ability to attach at secondary sites and re-initiate cell division. In this study, we illuminate mechanisms that enable reversible matrix attachment by breast cancer cells. Matrix deprival triggered AMPK activity and concomitantly inhibited AKT activity by upregulating the AKT phosphatase PHLPP2. The resultant pAMPKhigh/pAKTlow state was critical for cell survival in suspension, as PHLPP2 silencing also increased anoikis while impairing autophagy and metastasis...
January 16, 2018: Cancer Research
https://www.readbyqxmd.com/read/29339084/mir-613-inhibits-cell-migration-and-invasion-by-downregulating-daam1-in-triple-negative-breast-cancer
#10
Huaping Xiong, Ting Yan, Weijie Zhang, Fangfang Shi, Xuesong Jiang, Xiaohua Wang, Shoushan Li, Ying Chen, Cheng Chen, Yichao Zhu
Dishevelled-associated activator of morphogenesis 1 (Daam1) is a formin protein and participates in regulating cell migration of triple-negative breast cancer (TNBC) cells. The specific miRNA targeting Daam1 and mediating cell migration and invasion remains obscure. This experiment investigated the suppressive role of miR-613 in TNBC cells. The luciferase activity of Daam1 3'-untranslated region (3'-UTR) based reporters constructed in HEK-293T and MCF-7 cells suggested that Daam1 was the target gene of miR-613...
January 12, 2018: Cellular Signalling
https://www.readbyqxmd.com/read/29338448/the-safety-of-palbociclib-for-the-treatment-of-advanced-breast-cancer
#11
Tom Degenhardt, Rachel Wuerstlein, Tanja Eggersmann, Nadia Harbeck
Despite improvements in the diagnosis and management of early stage breast cancer, about one third of the patients still progress to metastatic disease. Most of the patients with metastatic breast cancer have a hormone receptor positive and human epidermal growth factor receptor 2 negative subtype with a median survival of more than 3 years. For these patients, endocrine therapy with its favorable toxicity profile is the current standard of care. However, patients with metastatic breast cancer have an incurable disease...
January 17, 2018: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/29337140/characteristics-and-prognostic-factors-for-patients-with-her2-overexpressing-breast-cancer-and-brain-metastases-in-the-era-of-her2-targeted-therapy-an-argument-for-earlier-detection
#12
Aki Morikawa, Rui Wang, Sujata Patil, Adi Diab, Jonathan Yang, Clifford A Hudis, Heather L McArthur, Kathryn Beal, Andrew D Seidman
BACKGROUND: Although brain metastases (BM) are associated with poor prognosis, patients with human epidermal growth factor receptor 2 (HER2) overexpressing (HER2+) breast cancer (BC) with BM who are treated with anti-HER2 therapy have a relatively longer survival after BM diagnosis compared with other subtypes and HER2+ patients previously untreated with anti-HER2 therapy. It is unclear if previously reported prognostic factors are applicable to patients with HER2+ BC in the era of HER2-targeted therapy...
December 21, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29337111/early-re-staging-and-molecular-subtype-shift-surveillance-of-locally-recurrent-or-metastatic-breast-cancer-a-new-pet-ct-integrated-precise-algorithm
#13
Wei Guo, Bing Hao, Nana Luo, Dan Ruan, Xiuyu Guo, Hao-Jun Chen, Hua Wu, Long Sun
Recurrent breast cancer poses considerable diagnostic and therapeutic challenges for clinic. Clinical suspicion of recurrence must be first confirmed by imaging studies. Then re-biopsy of suspected recurrence and metastasis in patients with breast cancer is recommended in the practice guidelines of the National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) to confirm whether the molecular subtype changes. It may change the individual treatment plan directly. Our research provided an integrated algorithm for locally recurrent or distant metastatic breast cancer, including early relapse detection and subsequently a new practical PET/CT imaging guide biopsy approach for surveilling molecular subtype shifts of the recurrent breast cancer...
January 11, 2018: Cancer Letters
https://www.readbyqxmd.com/read/29336662/body-mass-index-in-her2-negative-metastatic-breast-cancer-treated-with-first-line-paclitaxel-and-bevacizumab
#14
Laura Pizzuti, Domenico Sergi, Isabella Sperduti, Luigi Di Lauro, Marco Mazzotta, Claudio Botti, Fiorentino Izzo, Luca Marchetti, Silverio Tomao, Paolo Marchetti, Clara Natoli, Antonino Grassadonia, Teresa Gamucci, Lucia Mentuccia, Emanuela Magnolfi, Angela Vaccaro, Alessandra Cassano, Ernesto Rossi, Andrea Botticelli, Valentina Sini, Maria G Sarobba, Maria Agnese Fabbri, Luca Moscetti, Antonio Astone, Andrea Michelotti, Claudia De Angelis, Ilaria Bertolini, Francesco Angelini, Gennaro Ciliberto, Marcello Maugeri-Saccà, Antonio Giordano, Maddalena Barba, Patrizia Vici
The evidence emerged from the TOURANDOT trial encourages evaluating the role of anthropometric determinants on treatment outcomes in HER2-negative metastatic breast cancer patients treated with bevacizumab-including regimens. We thus analyzed data from a subgroup of these patients from a larger cohort previously assessed for treatment outcomes. Patients were included in the present analysis if body mass index values had been recorded at baseline. Clinical benefit rates, progression free survival and overall survival were assessed for the overall study population and subgroups defined upon molecular subtype...
January 16, 2018: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29336185/an-update-on-first-line-therapies-for-metastatic-breast-cancer
#15
Palma Fedele, Mariangela Ciccarese, Giammarco Surico, Saverio Cinieri
In recent years, outcomes of patients with metastatic breast cancer (MBC) have improved due to a greater understanding of the mechanisms of carcinogenesis in the development of newer molecularly targeted drugs, especially those as a front-line therapy. Remarkable improvements have been made in the treatment of hormone receptor positive (HR+) and Her2 positive MBC and currently targeted treatment strategies represent a valid first line treatment. Areas covered: Herein, the authors provide an overview of the first-line pharmacotherapies currently available for the treatment of MBC and provide their expert perspectives on the area...
January 16, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29334917/obesity-and-breast-cancer-outcomes-in-chemotherapy-patients-in-new-zealand-a-population-based-cohort-study
#16
J Mark Elwood, Sandar Tin Tin, Marion Kuper-Hommel, Ross Lawrenson, Ian Campbell
BACKGROUND: Obesity has been reported as an adverse prognostic factor in breast cancer, but inconsistently, and under-treatment with chemotherapy may occur. We provide the first assessment of obesity and breast cancer outcomes in a population-based, multi-ethnic cohort of New Zealand patients treated with chemotherapy. METHODS: All 3536 women diagnosed with invasive breast cancer in the Waikato region of New Zealand from 2000-2014 were registered and followed until last follow-up in specialist or primary care, death or Dec 2014; median follow-up 4...
January 15, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29334609/score-for-the-survival-probability-in-metastasis-breast-cancer-a-nomogram-based-risk-assessment-model
#17
Zhenchong Xiong, Guangzheng Deng, Xinjian Huang, Xing Li, Xinhua Xie, Jin Wang, Zeyu Shuang, Xi Wang
Purpose: Survival of metastatic breast cancer patient remains unknown and varies greatly from person to person. Thus, we aimed to construct a nomogram to quantify the survival probability of patients with metastatic breast cancer (MBC). Materials and methods: We had included 793 MBC patients and calculated trends of case fatality rate by Kaplan-Meier method and joinpoint regression. 634 patients with MBC between January 2004 and July 2011 and 159 patients with MBC between August 2011 and July 2013 were assigned to training cohort and internal validation cohort, respectively...
January 2, 2018: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/29334196/microfluidic-tumor-vascular-model-to-study-breast-cancer-cell-invasion-and-intravasation
#18
Supriya Nagaraju, Danh Truong, Ghassan Mouneimne, Mehdi Nikkhah
Cancer is a major leading cause of disease-related death in the world. The severe impact of cancer can be attributed to poor understanding of the mechanisms involved in earliest steps of the metastatic cascade, specifically invasion into the surrounding stroma and intravasation into the blood capillaries. However, conducting integrated biological studies of invasion and intravasation have been challenging, within in vivo models and traditional in vitro assay, due to difficulties in establishing a precise tumor microenvironment...
January 15, 2018: Advanced Healthcare Materials
https://www.readbyqxmd.com/read/29333945/remarkable-response-with-pembrolizumab-plus-albumin-bound-paclitaxel-in-2-cases-of-her2-positive-metastatic-breast-cancer-who-have-failed-to-multi-anti-her2-targeted-therapy
#19
Bian Li, Wang Tao, Zhang Shao-Hua, Q U Ze-Rui, Jin Fu-Quan, L I Fan, Jiang Ze-Fei
In clinical practice, one subgroup patients of breast cancer might have developed resistance to multi-anti-HER2 targeted drugs(trastuzumab,lapatinib and/or T-DM1) and can not benefit from the anti-HER2 targeted therapy continuously. We attempt to change the next therapic way for these patients.Two patients with metastatic breast cancer who have failed to multi-anti-HER2 targeted therapy were treated with pembrolizumab(2mg/Kg, day1) plus albumin-bound paclitaxel(125mg/m2, day1,8) every 3 weeks.CT evaluation and HER2 ECD test were performed every 2 cycles...
January 15, 2018: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29333281/controversies-and-consensus-of-neoadjuvant-chemotherapy-in-soft-tissue-sarcomas
#20
Herbert H Loong, Kwan-Hung Wong, Teresa Tse
Together with surgery and radiotherapy, systemic treatment with cytotoxic chemotherapy and molecular targeted agents is one of the main therapeutic pillars in the treatment of soft-tissue sarcomas and is the mainstay of treatment in patients with advanced or metastatic disease. Unlike other more common malignancies such as breast and colorectal cancer, the role of chemotherapy when used in the adjuvant setting in soft-tissue sarcomas is less well defined. Results from prior studies have been conflicting, in part due to the heterogeneity and rarity of the disease, and large-scale meta-analysis has been performed to address this issue...
2018: ESMO Open
keyword
keyword
62249
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"